Quick Listen: Scrip’s Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: will a new oral antiviral be transformative for COVID?; OX40 drugs gain prominence in atopic dermatitis; J&J adds pace to RSV vaccine race; Sarepta leapfrogs Pfizer in DMD gene therapy; and how real-world evidence and randomized trials might go together.

audio catch-up on the week's global biopharma highlights

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 8 October 2021, including: will a new oral antiviral be transformative for COVID?; OX40 drugs gain prominence in atopic dermatitis; Johnson & Johnson adds pace to RSV vaccine race; Sarepta Therapeutics, Inc. leapfrogs Pfizer Inc. in DMD gene therapy; and how real-world evidence and randomized trials might go together.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.  

Stories mentioned in this episode:

(Also see "Merck’s Oral Antiviral Data In COVID-19 May Change Pandemic Outlook" - Scrip, 1 Oct, 2021.)

 

(Also see "Sanofi And Amgen Make The Case For OX40 Drugs In Atopic Dermatitis" - Scrip, 4 Oct, 2021.)

(Also see "J&J Sets The Pace In Race To $10bn RSV Vaccine Market" - Scrip, 4 Oct, 2021.)

(Also see "Sarepta Leapfrogs Pfizer In The US, Launching DMD Gene Therapy Pivotal Trial" - Scrip, 4 Oct, 2021.)

(Also see "Janssen’s Sarich: Randomized Controlled Trials, Real-World Evidence Go Best Together" - Scrip, 4 Oct, 2021.)

Open Media